within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CJ02_Lemborexant;
model Lemborexant 
   extends Pharmacolibrary.Drugs.ATC.N.N05CJ02;

  annotation(Documentation(
    info ="<html><body><p>Lemborexant is a dual orexin receptor antagonist used for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. It is an orally active, prescription hypnotic agent approved for adults by regulatory agencies such as the FDA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult subjects (aged 18–88), both male and female, primarily following oral administration in clinical and Phase I studies.</p><h4>References</h4><ol><li><p>Landry, I, et al., &amp; Reyderman, L (2021). Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females. <i>Clinical pharmacology in drug development</i> 10(9) 1089–1098. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.953&quot;>10.1002/cpdd.953</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34107159/&quot;>https://pubmed.ncbi.nlm.nih.gov/34107159</a></p></li><li><p>Dayal, S, et al., &amp; Landry, I (2021). Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant. <i>Pharmacology research &amp; perspectives</i> 9(2) e00758–None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.758&quot;>10.1002/prp2.758</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33822479/&quot;>https://pubmed.ncbi.nlm.nih.gov/33822479</a></p></li><li><p>Landry, I, et al., &amp; Reyderman, L (2021). Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. <i>Pharmacology research &amp; perspectives</i> 9(2) e00734–None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.734&quot;>10.1002/prp2.734</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33689224/&quot;>https://pubmed.ncbi.nlm.nih.gov/33689224</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Lemborexant;
